Department of Intensive Care, Royal Free Hospital, London, United Kingdom of Great Britain and Northern Ireland.
Department of Cardiology, Royal Free Hospital, London, United Kingdom of Great Britain and Northern Ireland.
Cardiovasc Revasc Med. 2022 Feb;35:161-168. doi: 10.1016/j.carrev.2021.03.025. Epub 2021 Apr 6.
Robotic percutaneous coronary intervention (R-PCI) is a novel approach to performing percutaneous coronary intervention (PCI) whereby the operator can utilise remotely controlled technology to manipulate guidewires and catheter devices. This enables the procedure to be undertaken from within a radiation-shielded cockpit. Success in early trials has led to the release of commercially available robotic platforms which have now received regulatory approval and are available for use in clinical practice. Recent trials evaluating R-PCI have demonstrated high technical success rates with low complication rates. Despite this, a significant number of cases, particularly those with complex anatomy, still require at least partial conversion to a manual procedure. Advantages of R-PCI include accurate stent placement, reduced operator radiation exposure and a presumed reduction in orthopedic injuries. Limitations include current incompatibility with certain intravascular imaging catheters and the inability to manipulate multiple guidewires and stents simultaneously. Patients presenting with ST-elevation myocardial infarction requiring primary-PCI have also largely been excluded from existing R-PCI studies. Given these caveats, R-PCI remains a novel technology and has yet to become commonplace in cardiac catheterisation laboratories, however with increasing safety and feasibility data emerging, it is possible that R-PCI may form part of standard practice in the future.
机器人经皮冠状动脉介入治疗(R-PCI)是一种进行经皮冠状动脉介入治疗(PCI)的新方法,操作人员可以利用远程控制技术来操作导丝和导管设备。这使得该程序可以在辐射屏蔽的驾驶舱内进行。早期试验的成功导致了商业化的机器人平台的发布,这些平台现在已经获得监管批准,可用于临床实践。最近评估 R-PCI 的试验表明,该技术具有很高的技术成功率和较低的并发症发生率。尽管如此,仍有相当数量的病例,特别是那些具有复杂解剖结构的病例,仍需要至少部分转换为手动程序。R-PCI 的优点包括支架放置准确、操作人员辐射暴露减少以及假定减少骨科损伤。局限性包括目前与某些血管内成像导管不兼容,以及无法同时操作多根导丝和支架。需要进行直接 PCI 的 ST 段抬高型心肌梗死患者也主要被排除在现有的 R-PCI 研究之外。鉴于这些注意事项,R-PCI 仍然是一种新技术,尚未在心脏导管实验室中普及,但是随着越来越多的安全性和可行性数据的出现,R-PCI 有可能成为未来标准治疗的一部分。